Instruction for use: Hytrin

Trade name of the drug – Hytrin

Active substance: Terazosinum

Dosage Form: tablets

Composition (per tablet): "Start package": 1 tablet (white) contains terazosin hydrochloride 1 mg and 1 tablet (orange) - 2 mg; in blister 14 pcs. (Table 7. Each dosage), in one blister box.

1 tablet (orange) - 2 mg; per pack 28 pcs.

1 tablet (light brown) - 5 mg; per pack 28 pcs.

1 tablet (green) - 10 mg; per pack 28 pcs.

Pharmacotherapeutic group:

Alpha-blockers

Drugs affecting the metabolism of the prostate gland and correctors urodynamics

ATX G04CA03 Terazosin

The nosological classification (ICD-10)

I10 Essential (primary) hypertension: hypertension; Arterial hypertension; Arterial hypertension crisis course; Essential Hypertension; Essential hypertension; Essential hypertension; Essential hypertension; Essential hypertension; Primary hypertension; Arterial hypertension, complications of diabetes; The sudden increase in blood pressure; Hypertensive disorders of blood circulation; hypertensive condition; hypertensive crises; arterial Hypertension; malignant Hypertension; Hypertonic disease; hypertensive crises; accelerated hypertension; malignant hypertension; The aggravation of hypertensive disease; Transient hypertension; Isolated systolic hypertension

I15 Secondary hypertension: Arterial hypertension, complications of diabetes; hypertension; The sudden increase in blood pressure; Hypertensive disorders of blood circulation; hypertensive condition; hypertensive crises; hypertension; arterial Hypertension; malignant Hypertension; hypertensive crises; accelerated hypertension; malignant hypertension; The aggravation of hypertensive disease; Transient hypertension; hypertension; Arterial hypertension; Arterial hypertension crisis course; renovascular hypertension; Hypertension symptomatic; Renal hypertension; Renovascular hypertension; renovascular hypertension; Symptomatic hypertension

N40 Hyperplasia of prostate gland: Prostate adenoma; BPH; Prostatauxe; prostate Hypertrophy; Dysuric disorders caused by benign prostatic hyperplasia; Dizuricheskie disorder with benign prostatic hyperplasia; Dysuria with prostate cancer; Benign prostatic giperpalaziya; Benign prostatic hyperplasia; Benign prostatic hyperplasia stages 1 and 2; Benign prostatic hyperplasia I degree; Benign prostatic hyperplasia II degree; Benign prostatic hypertrophy; The disease of the prostate gland; Acute urinary retention related to benign prostatic hyperplasia; Benign prostatic hyperplasia stages 1 and 2 in combination with prostatitis; paradoxical ischuria

Pharmacological Properties of Hytrin

Pharmachologic effect - Mode of action - alpha adrenoliticheskoe.

Selectively blocks postsynaptic alpha1-adrenergic receptors decreases the tonus of smooth muscle prostate vessels.

Pharmacodynamics

In patients with BPH normalizes urination (alpha1-adrenergic blockade triangle smooth muscle of the bladder neck and proximal urethra, the prostate gland). It is an extension resistance (arterial) blood vessels, reduces peripheral vascular resistance and blood pressure. Reduces pre- and afterload on the heart. Unlike selective blockers, alpha 1 and alpha2 adrenergic receptors causes marked tachycardia. It has a lipid-lowering activity.

Pharmacokinetics

Quickly and completely absorbed in the digestive tract. Cmax plasma levels achieved after 1 hour. Intensively binds to blood protein. T1 / 2 -. 12 hours is metabolized in the liver. About 10% is excreted unchanged in the urine and 20% - through the intestines; remainder is excreted in the form of metabolites.

Indications for Hytrin

Prostate adenoma, arterial hypertension.

Contraindications for Hytrin

Hypersensitivity.

Hytrin Dosage and Administration

Inside. Hypertension: start with receiving the lowest dose (1 mg), and then it increased to 1-5 mg / day in 1-2 reception. The maximum daily dose - 20 mg.

Prostate adenoma: first taking 1.2 mg, then - 5 mg (clinical effect is achieved). In case of cancellation of treatment, reduce the dose gradually (over several days).

Side effect of Hytrin

Asthenia, violation of clarity of vision, nasal congestion, nausea, peripheral edema, tendency to increase body weight in patients; lower hematocrit, hemoglobin, white blood cells, total protein and albumin in the blood.

Interaction

It enchases (Mutually) the effect of others. Antihypertensive drugs (dosage should be adjusted). Compatible with analgesic, anti-inflammatory and cardiovascular agents, corticosteroids, and others.

SPECIAL INSTRUCTIONS for Hytrin

It should be borne in mind the effect of "first dose" (orthostatic collapse). Upon termination of the treatment for a few days or longer therapy should be carried out on the original scheme.

Storage conditions of Hytrin

The temperature is not above 40 ° C.

Keep out of the reach of children.

Shelf life

3 years.

Do not use beyond the expiration date printed on the package.